Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

costs and expenses for the 2013 period was primarily attributable to the timing of educational and marketing programs, combined with lower personnel costs for the company's hospital sales specialists. These reductions were partially offset by higher legal expenses incurred during the 2013 period related to the company's intellectual property litigation.

As of March 31, 2013, Cadence held cash, cash equivalents and short-term investments of $64.2 million, an increase of $2.1 million from the $62.1 million at December 31, 2012. Net accounts receivable at March 31, 2013, was $8.9 million.

GuidanceAs of May 2, 2013, Cadence is increasing its guidance to reflect the impact of the deferred revenue recognized in the first quarter of 2013. It now expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013, will range from approximately $97.0 million to $103.0 million.

Conference Call and Webcast on May 2, 2013 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) Cadence management will host a conference call on May 2, 2013, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investors page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call. Cadence uses the Investors portion of its website as one means of disclosing material non-public information, and investors are encouraged to monitor Cadence's website in addition to following the company's press releases, SEC filings and public conference calls and webcasts.

About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 1
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 DuPont Pioneer ... business as vice president of Agricultural Biotechnology (ABT), effective ... where he served most recently as president, chief executive ... and business leadership in the seed and crop protection ... Paul E. Schickler , president of DuPont Pioneer. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber ... biotechnology company producing sustainable chemicals, today announced that the ... full their option to purchase an additional 420,000 ... price of $12.00 per share, less underwriting discounts ... underwritten public offering of 2,800,000 shares of common ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... 4, 2008, SAN DIEGO, Oct. 27 Neurocrine ... Gorman, President and Chief,Executive Officer of Neurocrine Biosciences will ... New York., The live presentation takes place Tuesday, ... a.m. Pacific Time (PT). The presentation will,be simultaneously webcast ...
... BioTrends Research Group, Inc. was,named one of ... Philadelphia region by the Philadelphia 100(R), a joint ... Entrepreneurs, Forum of,Greater Philadelphia, and the Philadelphia Business ... "This recognition is a testament to the ...
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today ... financial results will be released Friday, November 7,2008. ... Owusu-Akyaw, President and,Chief Executive Officer, as well as ... 2008, at 9:00 a.m. Eastern time. You are ...
Cached Biology Technology:Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference 2
(Date:7/22/2014)... spot with natural tourism resources, a recent study revealed a ... Geoscience and Mineral Resources (KIGAM) indicated that there are the ... 5,000 years ago. That is the first time to actually ... volcano 5,000 years ago in the inland part of the ... The research team led by Dr. Jin-Young Lee confirmed in ...
(Date:7/22/2014)... The darker side of meerkats which sees them prevent ... explained in a new study. , Research into the desert ... pair and many adult helpers shows that the alpha ... breed. , The study shows how this way of life, ... can prove effective despite its sinister side. , Dominant ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... of North Africa,s major droughts of centuries past, reveals ... year 1179. The first multi-century drought reconstruction that ... droughts during the 13th and 16th centuries and the ... international research team figured out northwest Africa,s climate history ...
... University of Rochester Medical Center scientists discovered a defect ... earliest stages of abnormal skull development in newborns, known as ... pathways set off a cascade of events that regulate bone ... published May 25, 2010, in the journal Science Signaling ...
... Association today launched a first-of-its-kind educational tool to ... college and university professors provide evidence to support ... academic world is commonly predicated on judging a ... Sally T. Hillsman, ASA,s Executive Officer. "While teaching ...
Cached Biology News:20th century one of driest in 9 centuries for northwest Africa 220th century one of driest in 9 centuries for northwest Africa 3Stem-cell disruption induces skull deformity, UR study shows 2American Sociological Association launches first-of-its-kind teaching tool 2American Sociological Association launches first-of-its-kind teaching tool 3
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Mouse Antibody to Human Cytokeratin TYPE ... Basic (Type II) keratins. Including epidermal cell ... at 58kD, 65kD and 67kD. Broad keratin ... oesophagus and cornea. Immunogen: ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
Biology Products: